Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05297864 · ClinicalTrials.gov registry record · Phase 2
PARP Inhibition for Gliomas (PI-4G or π4g)
A Phase 2 study, sponsored by University of Oklahoma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT05297864 is a Phase 2 study that was terminated before completion, run by University of Oklahoma. The registered enrollment target is 15 participants.
The verdict
NCT05297864, a Phase 2 study, was terminated before completion, sponsored by University of Oklahoma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to determine what effects (good and bad) niraparib has on patients with recurrent brain cancer.
Interventions
- DRUG Niraparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-06-09 |
| Est. Completion | 2024-02-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05297864
The ClinicalTrials.gov registry entry for NCT05297864 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Niraparib is the first listed.
NCT05297864 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05297864 about?
NCT05297864 is a clinical study titled "PARP Inhibition for Gliomas (PI-4G or π4g)". The purpose of this study is to determine what effects (good and bad) niraparib has on patients with recurrent brain cancer.
What is the current status of trial NCT05297864?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2022-06-09. Estimated completion is 2024-02-06.
What interventions are being tested in trial NCT05297864?
The interventions under investigation include: Niraparib (DRUG).
Who is sponsoring clinical trial NCT05297864?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.